Next Article in Journal
Systematic Review on Pathophysiological Complications in Severe COVID-19 among the Non-Vaccinated and Vaccinated Population
Previous Article in Journal
Assessment of In Vitro Immunostimulatory Activity of an Adjuvanted Whole-Cell Inactivated Neisseria gonorrhoeae Microparticle Vaccine Formulation
Previous Article in Special Issue
A Needs-Based Analysis of Teaching on Vaccinations and COVID-19 in German Medical Schools
 
 
Article

Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021)

1
Sendai Viralytics LLC, 23 Nylander Way, Acton, MA 01720, USA
2
Medusa Project SIA, Krisjana Barona iela 5-2, LV-1050 Rīga, Latvia
*
Author to whom correspondence should be addressed.
Academic Editors: Ralph A. Tripp and Scott Anthony
Vaccines 2022, 10(7), 984; https://doi.org/10.3390/vaccines10070984
Received: 1 June 2022 / Revised: 15 June 2022 / Accepted: 16 June 2022 / Published: 21 June 2022
(This article belongs to the Collection COVID-19 Vaccines and Vaccination)
The goal of this study was to evaluate the epidemiological effectiveness of the Sputnik V and EpiVacCorona vaccines against COVID-19. This work is a retrospective cohort study of COVID-19 patients. The cohort created by the Moscow Health Department included more than 300,000 infected people who sought medical care in June and July 2021. Analysis of data revealed a tendency for the increase in the Sputnik V vaccine effectiveness (VE) as the severity of the disease increased. Protection was the lowest for mild disease, and it was more pronounced for severe disease. We also observed a decrease in VE with increasing age. For the youngest group (18–50 years old), the estimated VE in preventing death in June 2021 was 95% (95% CI 64–100), and for the older group (50+ years old), it was 74% (95% CI 67–87). The estimated protection against a severe form of the disease in the 18–50-year-old group was above 81% (CI 95% 72–93), and in the 50+ years-old group, it was above 68% (CI 95% 65–82). According to our analysis, EpiVacCorona proved to be an ineffective vaccine and therefore cannot protect against COVID-19. View Full-Text
Keywords: COVID-19; vaccine effectiveness; SARS-CoV-2; Delta variant; Sputnik V vaccine; EpiVacCorona vaccine; medical informatics COVID-19; vaccine effectiveness; SARS-CoV-2; Delta variant; Sputnik V vaccine; EpiVacCorona vaccine; medical informatics
Show Figures

Graphical abstract

MDPI and ACS Style

Matveeva, O.; Ershov, A. Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021). Vaccines 2022, 10, 984. https://doi.org/10.3390/vaccines10070984

AMA Style

Matveeva O, Ershov A. Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021). Vaccines. 2022; 10(7):984. https://doi.org/10.3390/vaccines10070984

Chicago/Turabian Style

Matveeva, Olga, and Alexander Ershov. 2022. "Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021)" Vaccines 10, no. 7: 984. https://doi.org/10.3390/vaccines10070984

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop